Clinical Trials

A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Receiv

Cancer Type

Breast

ClinicalTrials.gov Identifier

NCT06393374

Principal Investigator

Virginia Kaklamani, MD, DSc

For more information about this study
View Details

About This Study

This clinical study will evaluate MK-2870 plus pembrolizumab versus TPC for the treatment of participants with TNBC who did not achieve pCR at surgery following neoadjuvant therapy with pembrolizumab plus chemotherapy.